Skip to main content
    E

    Embecta Corp (EMBC)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $6.25
    -0.21 (-3.25%)

    Market Cap: $366.02M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Embecta Corp (EMBC) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Embecta (EMBC) trades at 3.1x trailing earnings and 0.3x sales. Its P/E of 3.1x is below its 5-year median of 5.0x. The median P/E across 6 similar companies is 24.8x.

    Current Multiples

    Its enterprise value is 5.6x its EBITDA. Its free cash flow yield is 46.5%.

    MultipleValue
    P/E (trailing)3.1x
    Forward P/EN/A
    Price to sales0.3x
    EV/EBITDA5.6x
    Price to FCF2.2x
    EV/FCF9.7x
    PEGN/A
    FCF yield46.5%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/E3.1x5.0xN/A
    P/S0.3x0.8xN/A
    Medians of month-end values through Oct 2026: 50 to 55 months (5-year).

    Valuation History

    Over the 4 year ends shown, its P/E ranged from 3.9x in 2025 to 8.2x in 2024. 2025 was the lowest of those years.

    Year endPriceP/EP/S
    2025$11.883.9x0.6x
    2024$20.658.2x1.1x
    2023$18.937.2x1.0x
    2022$25.295.3x1.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About EMBC

    Is EMBC stock overvalued?

    GNG's valuation label for EMBC is Undervalued. Its P/E of 3.1x compares with a median of 24.8x across 6 similar companies.

    What is EMBC's price to sales ratio?

    Embecta has a price to sales ratio of 0.3x.

    What is Embecta's average P/E ratio over 5 years?

    Embecta's median P/E over the last 5 years is 5.0x, from 50 month-end values through Oct 2026.